Sinocare announced recently that it successfully defended itself in court against trademark infringement claims brought by Abbott (NYSE:ABT).

G6 continuous glucose monitor (CGM) receivers deliver glucose readings and alerts. However, certain devices may experience an ...

The FDA today issued an alert around a safety concern regarding diabetes devices that rely on smartphones to deliver critical ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management.

Embecta (Nasdaq:EMBC) shares ticked up before hours today on first-quarter results that came in ahead of the consensus ...

(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

Systems (Nasdaq:KRMD) announced today that it signed a development agreement with a global pharmaceutical company.

Abbott (NYSE:ABT) is launching a new initiative that takes a look at some of the stigmas and stereotypes that come with ...

Fractyl Health is cutting nearly a fifth of its workforce as it streamlines resources and shifts focus toward certain ...

Modular Medical develops patented insulin delivery technologies, aiming to improve access to glycemic control. Its founder, ...